Custirsen

Drug Profile

Custirsen

Alternative Names: Custirsen-sodium; ISIS 112989; OGX-011; TV-1011

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer OncoGenex Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Clusterin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 23 Feb 2017 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Canada (IV)
  • 23 Feb 2017 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top